MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

* agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastases * Native and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.

The first presentation examines agenT-797 alone and in combination with botensilimab and balstilimab (BOT+BAL) in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases. This preclinical research supports the rationale for the ongoing Phase 2 trial at Scripps, led by Darren Sigal, M.D., evaluating the combination in patients with previously treated microsatellite-stable (MSS) metastatic colorectal cancer with liver metastases (NCT07550088).